News for MITO Stock

Stealth BioTherapeutics Corp Announces Completion of Merger Stealth BioTherapeutics Announces SBT-272 Data Updates and Orphan Drug Designation for the Treatment of Amyotrophic Lateral Sclerosis (ALS) Stealth BioTherapeutics Corp to Hold Extraordinary General Meeting of Shareholders Stealth BioTherapeutics Announces Departure of Chief Financial Officer Stealth BioTherapeutics to Participate in Upcoming Ultra-Rare Disease Events Stealth BioTherapeutics Corp Enters Definitive Agreement for Going Private Transaction STEALTH BIOTHERAPEUTICS ANNOUNCES RECEIPT OF NON-COMPLIANCE NOTICE FROM NASDAQ Stealth BioTherapeutics Corp Announces Receipt of Preliminary Non-Binding Proposal Stealth BioTherapeutics Granted Pre-NDA Meeting for Elamipretide as a Potential Treatment for Barth Syndrome Stealth BioTherapeutics Presents New SBT-272 Data Demonstrating Improvement in Upper Motor Neuron Function in ALS Disease Model at Keystone Neurodegeneration Symposium Stealth BioTherapeutics Receives Orphan Drug Designation from the European Medicines Agency for Elamipretide for the Treatment of Myopathic Mitochondrial DNA Depletion Syndrome Stealth BioTherapeutics Announces Data from the Phase 2 ReCLAIM-2 Study of Elamipretide in Geographic Atrophy at the Clinical Trials at the Summit Meeting 2022 Stealth BioTherapeutics Receives Orphan Drug Designation from FDA for Elamipretide for Treatment of Duchenne Muscular Dystrophy STEALTH BIOTHERAPEUTICS ANNOUNCES DATA FROM RECLAIM-2 PHASE 2 TRIAL OF ELAMIPRETIDE IN GEOGRAPHIC ATROPHY Stealth BioTherapeutics Announces $8.5 Million in Equity Financings Stealth BioTherapeutics Announces New SBT-272 Data and Trial Initiation Stealth BioTherapeutics Receives Orphan Drug Designation from FDA for Elamipretide for the Treatment of Friedreich's Ataxia Stealth BioTherapeutics Announces New Data on Complement Gene Expression and Cell Survival in Dry AMD to be Presented at ARVO (2022) Stealth BioTherapeutics to Host Virtual Event on the Potential of Elamipretide in Treatment of Geographic Atrophy in Dry Age-Related Macular Degeneration Stealth BioTherapeutics Showcases New Duchenne Muscular Dystrophy Nonclinical Data at the 2022 Muscular Dystrophy Association and Clinical and Scientific Conference Stealth BioTherapeutics to Present at Upcoming March Investor Conferences Stealth BioTherapeutics to Present at Mitochondria-Targeted Drug Development Summit Last Patient Completes Treatment in Stealth BioTherapeutics' Phase 2 Geographic Atrophy Clinical Trial Stealth BioTherapeutics Receives Nasdaq Notification Regarding Minimum Market Value Of Publicly Held Shares Requirement Stealth BioTherapeutics Announces Oral Presentation of New Duchenne Muscular Dystrophy Data at the 2022 Muscular Dystrophy Association Clinical and Scientific Conference Stealth BioTherapetuics Receives Nasdaq Notifications Regarding Minimum Bid And Market Value Requirements Stealth BioTherapeutics to Present at 2022 H.C. Wainwright BioConnect Virtual Conference Stealth BioTherapeutics Reports Positive Pre-IND Meeting for Duchenne Muscular Dystrophy Stealth BioTherapeutics Provides Update On Clinical Stage Rare Disease Programs Stealth BioTherapeutics Reports Third Quarter 2021 Financial Results and Recent Business Highlights Stealth BioTherapeutics to Report Third Quarter Financial Results on Thursday, November 11 Stealth BioTherapeutics Receives Refusal to File Letter from the FDA Stealth BioTherapeutics Presents Positive SBT-272 Preclinical Data at 2021 Annual Northeast Amyotrophic Lateral Sclerosis (NEALS) Meeting Horizon Technology Finance Provides Third Quarter 2021 Portfolio Update Stealth BioTherapeutics Completes a $25 Million Debt Financing with Horizon Technology Finance Stealth BioTherapeutics Presents Positive SBT-272 Preclinical Data at International Parkinson and Movement Disorder Society Virtual Congress 2021 Stealth BioTherapeutics to Showcase Leadership in Retinal Mitochondrial Health with Clinical Updates at Ophthalmic Conferences Stealth BioTherapeutics to Present at Upcoming September Virtual Investor Conferences Stealth BioTherapeutics Submits Elamipretide New Drug Application to FDA for Treatment of Barth Syndrome Stealth BioTherapeutics Strengthens IP Portfolio with Issuance of U.S. Patents Covering Elamipretide for Barth Syndrome Stealth BioTherapeutics to Present at H.C. Wainwright Ophthalmology Virtual Healthcare Conference Stealth BioTherapeutics Reports Second Quarter 2021 Financial Results And Recent Business Highlights Stealth BioTherapeutics to Report Second Quarter Financial Results on Thursday, August 5 Stealth BioTherapeutics Joins the Rare Disease Company Coalition Stealth BioTherapeutics Receives Orphan Drug Designation from the European Medicines Agency for Elamipretide for the Treatment of Barth Syndrome Stealth BioTherapeutics to Present at Jefferies Virtual Healthcare Conference Stealth BioTherapeutics Reports First Quarter 2021 Financial Results And Recent Business Highlights Stealth BioTherapeutics Announces Additional Development Financing to Advance Elamipretide Clinical Trials Stealth BioTherapeutics Announces Poster Presentation at American College of Cardiology (ACC) Annual Meeting Stealth BioTherapeutics to Present at Upcoming Investor Conferences in May Stealth BioTherapeutics to Report First Quarter Financial Results on Tuesday, May 18, 2021 Stealth BioTherapeutics Showcases Data for Elamipretide in Dry Age-Related Macular Degeneration at the 2021 ARVO Annual Meeting Stealth BioTherapeutics Announces Poster Presentation at the 2021 Association for Research in Vision and Ophthalmology (ARVO) Virtual Annual Meeting Stealth BioTherapeutics CEO to Give Keynote Presentation at Mitochondria-Targeted Drug Development Summit Stealth BioTherapeutics Reports Fiscal Year 2020 Financial Results And Recent Business Highlights Stealth BioTherapeutics to Report Full Year 2020 Financial Results on Tuesday, April 6, 2021 Stealth BioTherapeutics Announces Promotion of Marty Redmon to Chief Research & Development Officer Stealth BioTherapeutics to Present at Upcoming Investor Conferences in March Stealth BioTherapeutics Completes Enrollment of Phase 2 Study in Dry Age-Related Macular Degeneration with Geographic Atrophy Stealth BioTherapeutics Announces Pricing Of $4.7 Million Registered Direct Offering Of American Depositary Shares Stealth BioTherapeutics to Participate in Upcoming January Investor Conferences Stealth BioTherapeutics Granted Pre-NDA Meeting For Elamipretide As A Treatment For Cardiomyopathy In Barth Syndrome Stealth BioTherapeutics Announces Elamipretide Clinical Data to be Presented at the 13th International Conference on Cachexia, Sarcopenia and Wasting Diseases Stealth BioTherapeutics Announces Appointment of Eve E. Slater, M.D., F.A.C.C. to its Board of Directors Stealth BioTherapeutics Announces Closing of $3.2 Million Registered Direct Offering Stealth BioTherapeutics Announces $3.2 Million Registered Direct Offering Stealth BioTherapeutics Reports Third Quarter 2020 Financial Results And Recent Business Highlights Stealth BioTherapeutics Announces Development Financing To Advance Elamipretide Clinical Trials Stealth BioTherapeutics to Report Third Quarter 2020 Financial Results on Thursday, November 5, 2020 Stealth BioTherapeutics Announces Poster Presentation at American Society of Human Genetics (ASHG) Virtual Annual Meeting Stealth BioTherapeutics Announces Poster Presentation at 2020 Annual NEALS Meeting Stealth BioTherapeutics to Present at Upcoming Investor Conferences in September Stealth BioTherapeutics Reports Second Quarter 2020 Financial Results and Recent Business Highlights Stealth BioTherapeutics to Report Second Quarter 2020 Financial Results on Thursday, August 6, 2020